Matrix Capital Management Company, LP Incyte Corp Transaction History

Matrix Capital Management Company, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $122 Million - $166 Million	-1,934,347 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $151 Million - $180 Million	-2,077,500 Reduced 51.78%	1,934,347 $144 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $317,800 - $440,850	-5,000 Reduced 0.12%	4,011,847 $345 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $35.1 Million - $42 Million	-600,000 Reduced 13.0%	4,016,847 $255 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $36.4 Million - $50.3 Million	598,900 Added 14.91%	4,616,847 $309 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $101 Million - $123 Million	1,217,731 Added 43.49%	4,017,947 $335 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $49.6 Million - $61.8 Million	530,000 Added 23.35%	2,800,216 $265 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $248 Million - $314 Million	2,270,216	2,270,216 $265 Million

641

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.9B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Matrix Capital Management Company, LP, based on Form 13F filings with the SEC.

Stay updated on Matrix Capital Management Company, LP with notifications on news.